Assessment of EGFR gene mutations in circulating free DNA in monitoring of response to EGFR tyrosine kinase inhibitors in patients with lung adenocarcinoma

Nicoś, Marcin; Wojas‐Krawczyk, Kamila; Krawczyk, Paweł; Chmielewska, Izabela; Wójcik-Superczyńska, Magdalena; Reszka, Katarzyna; Kieszko, Robert; Góra-Florek, Anna; Dudek, Małgorzata; Świniuch, Daria; Papiewski, Wojciech; Całka, Paulina; Ciesielka, Marzanna; Milanowski, Janusz

doi:10.5114/aoms.2019.89217

Cited by 1 publication

(2 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Soon after these observations, in 2016, the FDA approved the first quantitative PCR (qPCR) test for detecting an EGFR mutation in plasma cfDNA, which was concordant with tissue in 80% [ 54 ]. Therefore, patients with negative results of the mutation in the EGFR gene in liquid biopsy should be re-tested from the tissue sample [ 55 , 56 ]. Interestingly, the application of NGS techniques increased the concordance rate between these two diagnostic materials by only up to 85% [ 57 ].…”

Section: Liquid Biopsy—diagnostic Issuesmentioning

confidence: 99%

“…Therefore, early detection of T790M mutation in the liquid biopsy of NSCLC allows us to adjust the treatment regimen and continue the effective therapy [ 125 ]. In one of our studies, we also indicated that sequential evaluation of EGFR gene status in consecutive liquid biopsies, using a qPCR technique, has a high value in monitoring the response to EGFR TKIs and allows for early detection of acquired resistance determined by T790M substitution when disease progression is not detected by computed tomography yet [ 55 ]. However, despite the methodological advancement, evaluation of cfDNA for T790M mutation indicates 70% sensitivity, and even 30% of patients with negative results require a re-biopsy of a progressed tumor, and this, in many cases, is challenging [ 126 ].…”

Section: Role Of Liquid Biopsy In the Monitoring Of Response To Perso...mentioning

confidence: 99%

See 1 more Smart Citation

The Overview of Perspectives of Clinical Application of Liquid Biopsy in Non-Small-Cell Lung Cancer

Bożyk

Nicoś

2022

Life

View full text Add to dashboard Cite

The standard diagnostics procedure for non-small-cell lung cancer (NSCLC) requires a pathological evaluation of tissue samples obtained by surgery or biopsy, which are considered invasive sampling procedures. Due to this fact, re-sampling of the primary tumor at the moment of progression is limited and depends on the patient’s condition, even if it could reveal a mechanism of resistance to applied therapy. Recently, many studies have indicated that liquid biopsy could be provided for the noninvasive management of NSCLC patients who receive molecularly targeted therapies or immunotherapy. The liquid biopsy of neoplastic patients harbors small fragments of circulating-free DNA (cfDNA) and cell-free RNA (cfRNA) secreted to the circulation from normal cells, as well as a subset of tumor-derived circulating tumor cells (CTCs) or circulating tumor DNA (ctDNA). In NSCLC patients, a longitudinal assessment of genetic alterations in “druggable” genes in liquid biopsy might improve the follow-up of treatment efficacy and allow for the detection of an early progression before it is detectable in computed tomography or a clinical image. However, a liquid biopsy may be used to determine a variety of relevant molecular or genetic information for understanding tumor biology and its evolutionary trajectories. Thus, liquid biopsy is currently associated with greater hope for common diagnostic and clinical applications. In this review, we would like to highlight diagnostic challenges in the application of liquid biopsy into the clinical routine and indicate its implications on the metastatic spread of NSCLC or monitoring of personalized treatment regimens.

show abstract

Section: Liquid Biopsy—diagnostic Issuesmentioning

confidence: 99%

Section: Role Of Liquid Biopsy In the Monitoring Of Response To Perso...mentioning

confidence: 99%

The Overview of Perspectives of Clinical Application of Liquid Biopsy in Non-Small-Cell Lung Cancer

Bożyk

Nicoś

2022

Life

View full text Add to dashboard Cite

show abstract

Assessment of EGFR gene mutations in circulating free DNA in monitoring of response to EGFR tyrosine kinase inhibitors in patients with lung adenocarcinoma

Cited by 1 publication

References 13 publications

The Overview of Perspectives of Clinical Application of Liquid Biopsy in Non-Small-Cell Lung Cancer

The Overview of Perspectives of Clinical Application of Liquid Biopsy in Non-Small-Cell Lung Cancer

Contact Info

Product

Resources

About